% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • bioimmunomabman bioimmunomabman Apr 23, 2013 9:10 AM Flag


    SAN DIEGO, April 23, Apr 23, 2013 (GLOBE NEWSWIRE via COMTEX) -- Trius
    Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of a large,
    late-stage human study, called ESTABLISH 2, and multiple other clinical studies
    from its experimental antibiotic, tedizolid phosphate (TR-701), will be
    presented in poster and oral presentations at the European Congress of Clinical
    Microbiology and Infectious Diseases (ECCMID) meeting in Berlin from April
    27-30. A total of three tedizolid-related posters and one oral presentation have
    been accepted for presentation, including clinical and safety results.
    The clinical abstracts examine the effect of tedizolid in patients with acute
    bacterial skin and skin structure infections (ABSSSI), as well as cardiac and
    medication interaction safety trials. The abstracts include a poster
    presentation from the ESTABLISH 2 trial, the second of two late-stage or Phase 3
    studies needed for U.S. and E.U. regulatory filings. As in the ESTABLISH 1
    study, which tested the pill form of tedizolid, the ESTABLISH 2 intravenous (IV)
    to pill transition study captured the endpoints for ABSSSI established by both
    the U.S. Food and Drug Administration (FDA) and the European Medicines Agency
    (EMA). These presentations mark the first time ESTABLISH 2 data are being
    presented at a major medical meeting. Top-line results, reported in March 2013,
    showed that tedizolid achieved all primary and secondary efficacy outcomes after
    a short course of therapy using one-tenth the amount of total drug versus the
    comparator linezolid (Zyvox). Patients receiving tedizolid also showed numerical
    improvements in key safety and tolerability measurements in the complete study
    "The results of ESTABLISH 2 combined with those from ESTABLISH 1 and additional
    clinical studies support the differentiated profile of tedizolid as a potential
    new treatment option for patients with severe skin infections," said Dr.
    Philippe Prokocimer, Chief Medical Officer of Trius.

    SortNewest  |  Oldest  |  Most Replied Expand all replies